Morningstar

Eli Lilly Weight-Loss Pill Becomes Available in U.S.

Provided by Dow Jones

By Nicholas G. Miller 




  Eli Lilly's Foundayo weight-loss pill is now available in the U.S. following the Food and Drug Administration's approval earlier this month, the company said. 



  The drug is available through Eli Lilly's direct sales platform and telehealth providers and is shipping to retail pharmacies, the company said. 



  Foundayo is Eli Lilly's attempt to counter Novo Nordisk's successful launch of a pill version of its Wegovy drug, which it has been selling since the start of this year. 



  The companies are betting that the launch of GLP-1 pills will increase demand for the drugs, attracting those who are averse to needles or who don't think their weight is problematic enough to warrant an injection. 



  The starting dose of Foundayo will cost $149 a month, Eli Lilly said--the same as the starting dose of Novo Nordisk's GLP-1 pill. 





  Write to Nicholas G. Miller at nicholas.miller@wsj.com. 





  (END) Dow Jones Newswires



  April 09, 2026 07:17 ET (11:17 GMT)


Copyright (c) 2026 Dow Jones & Company, Inc.
  

					The articles, information, and content displayed on this webpage may
					include materials prepared and provided by third parties. Such
					third-party content is offered for informational purposes only and
					is not endorsed, reviewed, or verified by Morningstar.
				
 

					Morningstar makes no representations or warranties regarding the
					accuracy, completeness, timeliness, or reliability of any third-party
					content displayed on this site. The views and opinions expressed in
					third-party content are those of the respective authors and do not
					necessarily reflect the views of Morningstar, its affiliates, or employees.
				
 

					Morningstar is not responsible for any errors, omissions, or delays
					in this content, nor for any actions taken in reliance thereon.
					Users are advised to exercise their own judgment and seek independent
					financial advice before making any decisions based on such content.
					The third-party providers of this content are not affiliated with
					Morningstar, and their inclusion on this site does not imply any
					form of partnership, agency, or endorsement.
				
 

				Popular
				
 
  
 
 
 
 
3 Stocks to Sell and 3 Stocks to Buy for November
 
Plus, whether Microsoft, Alphabet, or Amphenol look attractive after earnings.  
 
 
David Sekera, CFA and Sarah Hansen 
 
 
 
This Once-Hot AI Stock Now Looks Deeply Undervalued
 
This chip stock looks cheap at a 30% discount, and its biggest growth years could still be ahead. 
 
 
William Kerwin, CFA 
 
 
 
The 10 Best Companies to Invest in Now
 
The stocks of these high-quality companies look cheap today. 
 
 
Tori Brovet 
 
 
 
He Tried Shorting Jim Cramer’s Stock Picks. It Cost Him More Than Money
 
Historian Joseph Moore explores why a promising product can fail as an investment and why beating the market may not be worth the effort. 
 
 
Christine Benz and Amy C. Arnott, CFA 
 
 
 
Tech Stocks Sell Off as Intel, Amazon Earnings Spook Investors
 
Underwhelming results have added to investor worries about AI spending. 
 
 
Vicky McKeever 
 
 
 
 

			Sponsor Center